Eda Altiok
Eda Altiok, Ph.D.
Senior Scientist
Biomedical Engineering
Menlo Park

Dr. Altiok’s areas of expertise encompass the in vitro and in vivo characterization of polymer conjugated drugs. In her doctoral research, she gained experience in E.coli and insect cell protein expression and characterized proteins and polymer conjugated drugs using size exclusion chromatography with enzyme linked immunosorbent assays (ELISA), multi-angle light scattering (SEC-MALS), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and dynamic light scattering (DLS).

Dr. Altiok’s additional areas of expertise include several in vitro assays for examining cell proliferation, migration, adhesion and tube formation. She has working knowledge of various experimental in vivo assays to examine the effect of drugs on vascularization in the cornea and retina using the corneal angiogenesis and oxygen-induced retinopathy models. She is proficient in multiple microscopy techniques including epifluorescence and confocal microscopy through which she examines complex three-dimensional distributions of distinct structures within biological tissue samples.

Dr. Altiok specializes in the delivery of protein-based drugs for treatment of neovascular diseases affecting the retina including diabetic retinopathy and wet macular degeneration. Specifically, her research focused on the use of a naturally occurring biopolymer called hyaluronic acid for conjugation of protein drugs in order to increase drug residence time in the vitreous of the eye. In her work, she has developed a novel rat-based intravitreal drug half-life model for examining the residence time of fluorescently tagged drugs in the vitreous.

Dr. Altiok has a Ph.D. in Bioengineering from University of California, Berkeley and a B.S. in Biological Sciences with an emphasis on Biomedical Engineering. Her doctoral research was supported by the National Science Foundation’s Graduate Research Fellowship.

CREDENTIALS & PROFESSIONAL HONORS

  • Ph.D., Bioengineering, University of California, Berkeley, 2016
  • B.S., Biological Sciences, Carnegie Institute of Technology, 2009
  • Turkish American Scientists & Scholars Assoc. (TASSA) Young Scholar Award, 2016

    National Science Foundation Graduate Research Fellowship, 2012-2015

    Outstanding Graduate Student Instructor Award, 2015

    William C. Ezell Fellowship-American Academy of Optometry, 2012 and 2013

    Minnie F. Turner Memorial Fund for Impaired Vision Research Award, 2012

    IAESTE Research Fellow (International Association for the Exchange of Students for Technical Experiences) in Melbourne, Australia, 2009-2010

LANGUAGES

  • Turkish

Publications

Altiok EI, Santiago-Ortiz JL, Svedlund FL, Zbinden A, Jha AK, Bhatnagar D, Loskill P, Jackson WM, Schaffer DV, Healy KE. Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro. Biomaterials. 2016 Jul 31;93:95-105.

Altiok EI, Browne S, Khuc E, Moran EP, Qiu F, Zhou K, Santiago-Ortiz JL, Ma JX, Chan MF, Healy KE. sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo. PloS one. 2016 Jun 3;11(6):e0155990.

Altiok EI. Improving Anti-VEGF Drugs in the Vitreous. Ph.D. Dissertation, University of California, Berkeley, December 2015.

Altiok EI, Ecoiffier T, Sessa R, Yuen D, Grimaldo S, Tran C, Li D, Rosner M, Lee N, Uede T, Chen L. Integrin Alpha-9 Mediated Lymphatic Valve Formation in Corneal Lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2015;56(11):6313-6319.

Bakhru S, Altiok EI, Delubac D, Sekula R, Hitchens K, Ho C, Zappe S. Enhanced cellular uptake and long-term retention of chitosan-modified iron-oxide nanoparticles for MRI-based cell tracking. International Journal of Nanomedicine. 2012; 7: 4613–4623.

Truong T, Altiok EI, Yuen D, Ecoiffier T, Chen L. Novel characterization of lymphatic valve formation during corneal inflammation. PLoS One. 2011; 6 (7): e21918.

Invited Oral Presentations

Altiok EI. Improving drug delivery to the retina. Turkish American Scientists and Scholars Association Conference. Chicago, IL; April 2016.

Altiok EI, Bhatnagar D, Santiago J, Jackson W, Schaffer D, Healy KE. Using multivalent VEGF antagonists for inhibition of angiogenesis in the retina. UC Berkeley Bioengineering Conference. Yosemite, CA; November 2014.

Altiok EI, Bhatnagar D, Santiago J, Jackson W, Schaffer D, Healy KE. Targeting angiogenesis in diabetic retinopathy and wet AMD using hyaluronic acid based VEGF antagonists. Koc University, Chemical and Biological Engineering seminar. Istanbul, Turkey; June 2014

Altiok EI, Bhatnagar D, Santiago J, Jackson W, Schaffer D, Healy KE. Inhibition of pathogenic angiogenesis in diabetic retinopathy with a hyaluronic acid based multivalent VEGF antagonist. Society for Biomaterials Conference. Denver, CO; March 2014.

Altiok EI, Jha A, Santiago J, Jackson W, Healy KE. Inhibition of pathogenic angiogenesis using a hyaluronic acid based multivalent VEGF antagonist. Biomedical Engineering Society Conference. Seattle, WA; September, 2013.

Patents

Publication number: WO2014165513 A2: Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof, 10/9/2014 (Amit K. Jha, Eda I. Altiok, Wesley M. Jackson, Kevin E. Healy).

Professional Affiliations

Association for Research in Vision and Ophthalmology

American Optometric Foundation

Biomedical Engineering Society

CREDENTIALS & PROFESSIONAL HONORS

  • Ph.D., Bioengineering, University of California, Berkeley, 2016
  • B.S., Biological Sciences, Carnegie Institute of Technology, 2009
  • Turkish American Scientists & Scholars Assoc. (TASSA) Young Scholar Award, 2016

    National Science Foundation Graduate Research Fellowship, 2012-2015

    Outstanding Graduate Student Instructor Award, 2015

    William C. Ezell Fellowship-American Academy of Optometry, 2012 and 2013

    Minnie F. Turner Memorial Fund for Impaired Vision Research Award, 2012

    IAESTE Research Fellow (International Association for the Exchange of Students for Technical Experiences) in Melbourne, Australia, 2009-2010

LANGUAGES

  • Turkish